biote (BTMD) Expected to Announce Earnings on Wednesday

biote (NASDAQ:BTMD) is projected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect biote to announce earnings of $0.03 per share and revenue of $46.1240 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

biote (NASDAQ:BTMD) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $44.94 million for the quarter, compared to analysts’ expectations of $46.02 million. biote had a negative return on equity of 25.72% and a net margin of 8.29%. On average, analysts expect biote to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

biote Stock Performance

Shares of NASDAQ:BTMD opened at $2.29 on Tuesday. The company has a market cap of $86.06 million, a P/E ratio of 5.20 and a beta of 1.64. The stock’s 50-day moving average is $2.21 and its 200-day moving average is $2.05. biote has a 52-week low of $1.27 and a 52-week high of $4.20.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BTMD. Weiss Ratings upgraded shares of biote from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 28th. Truist Financial raised shares of biote to a “strong-buy” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $2.75.

Hedge Funds Weigh In On biote

A number of large investors have recently made changes to their positions in BTMD. Quadrature Capital Ltd bought a new position in biote during the 4th quarter worth $38,000. Millennium Management LLC acquired a new stake in shares of biote during the 4th quarter worth approximately $40,000. Abel Hall LLC acquired a new stake in biote in the fourth quarter valued at about $45,000. Rothschild Wealth LLC bought a new stake in shares of biote during the fourth quarter worth $380,000. Finally, Marshall Wace LLP bought a new stake in shares of biote during the fourth quarter worth about $40,000. Institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.